"
Team:Paris Bettencourt/Project/Overview
From 2013.igem.org
Ewintermute (Talk | contribs) |
Ewintermute (Talk | contribs) |
||
| Line 87: | Line 87: | ||
<p> | <p> | ||
| - | + | <i>M. tuberculosis</i> grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to <i>E. coli</i>, where is is easy to screen for targeted small-molecule inhibitors. | |
</p> | </p> | ||
Revision as of 20:42, 3 October 2013
<body>
To defeat tuberculosis, we need new biotechnology. Our work will add 4 new tools to the anti-TB medical armamentarium. Detect - A CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. Target - An E. coli model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. Infiltrate - A E. coli strain capable of entering infected macrophages and lysing mycobacteria. Sabotage - A non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance.
Target
M. tuberculosis grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to E. coli, where is is easy to screen for targeted small-molecule inhibitors.
Infiltrate
An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, E. coli express lysteriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane.
+33 1 44 41 25 22/25
team2013@igem-paris.org 
